Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples

Transfusion

Volumn 50, Issue 8, 2010, Pages 1712-1721

  Yu, Mei Ying W ^a,b,c   Alter, Harvey J ^a,b,c   Virata Theimer, Maria Luisa A ^a,b,c   Geng, Yansheng ^a,b,c   Ma, Li ^a,b,c   Schechterly, Cathy A ^a,b,c   Colvin, Camilla A ^a,b,c   Luban, Naomi L C ^a,b,c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; VIRUS DNA; VIRUS ANTIBODY;

ADULT; ARTICLE; BLOOD DONOR; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; DNA SEQUENCE; ERYTHROCYTE TRANSFUSION; FEMALE; GENOTYPE; HUMAN; HUMAN PARVOVIRUS B19; INFECTION RISK; NUCLEOTIDE SEQUENCE; PARVOVIRUS INFECTION; PHYLOGENY; RECIPIENT; VIRUS TRANSMISSION; BLOOD; CASE REPORT; TRANSMISSION;

ADULT; ANTIBODIES, VIRAL; BLOOD DONORS; DNA, VIRAL; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN;

EID: 77955144845     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02591.x     Document Type: Article

References (51)

1. Young NS, Brown KE. Mechanisms of disease: parvovirus B19. N Engl J Med 2004 350 : 586 97.
2. Siegl G, Cassinotti P. Presence and significance of parvovirus B19 in blood and blood products. Biologicals 1998 26 : 89 94.
3. Yee TT, Cohen BJ, Pasi KJ, Lee CA. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol 1996 93 : 457 9.
4. Santagostino E, Mannucci PM, Gringeri A, Azzi A, Morfini M, Musso R, Santoro R, Schiavoni M. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization. Transfusion 1997 37 : 517 22.
5. Matsui H, Sugimoto M, Tsuji S, Shima M, Giddings J, Yoshioka A. Transient hypoplastic anemia caused by primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate [case report]. J Pediatr Hematol Oncol 1999 21 : 74 6.
6. Azzi A, Morfini M, Mannucci PM. The transfusion-associated transmission of parvovirus B19. Transfus Med Rev 1999 13 : 194 204.
7. Blümel J, Schmidt I, Effenberger W, Seitz H, Willkommen H, Brackmann HH, Löwer J, Eis-Hubinger AM. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion 2002 42 : 1473 81.
8. Wu CG, Mason B, Jong J, Erdman D, McKernan L, Oakley M, Soucie M, Evatt B, Yu MW. Parvovirus B19 transmission by a high-purity factor VIII concentrate. Transfusion 2005 45 : 1003 10.
9. Blood Products Advisory Committee. Nucleic acid testing of blood donors for human parvovirus B19 [Internet]. Rockville (MD) : U.S. Food and Drug Administration 1999. p. 144 222 cited 17 Jan 2010]. Available from: http://www.fda.gov/ohrms/dockets/ac/99/transcpt/3548t1b.pdf and http://www.fda.gov/ohrms/dockets/ac/99/transcpt/3548t1c.pdf
10. Brown KE, Young NS, Alving BM, Barbosa LH. Parvovirus B19: implications for transfusion medicine, summary of a workshop. Transfusion 2001 41 : 130 5.
11. Geng Y, Wu CG, Bhattacharyya SP, Tan D, Guo ZP, Yu MW. Parvovirus B19 DNA in factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing. Transfusion 2007 47 : 883 9.
12. Anderson MJ, Tsou C, Parker RA, Chorba TL, Woffe H, Tattersall P, Mortimer PP. Detection of antibodies and antigen of human parvovirus B19 by enzyme-linked immunosorbent assay. J Clin Microbiol 1986 24 : 522 6.
13. Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 1988 25 : 151 3.
14. Wong S, Brown KE. Development of an improved method of detection of infectious parvovirus B19. J Clin Virol 2006 35 : 407 13.
15. Modrof J, Berting A, Tille B, Klotz A, Forstner C, Rieger S, Aberham C, Gessner M, Kreil TR. Neutralization of human parvovirus B19 by plasma and intravenous immunoglobulins. Transfusion 2008 48 : 178 86.
16. Jordan J, Tiangco B, Kiss J, Koch W. Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang 1998 75 : 97 102.
17. Aubin JT, Defer C, Vidaud M, Maniez Montreuil M, Flan B. Large-scale screening for human parvovirus B19 DNA by PCR: application to the quality control of plasma for fractionation. Vox Sang 2000 78 : 7 12.
18. Weimer T, Streichert S, Watson C, Gröner A. High-titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation. Transfusion 2001 41 : 1500 4.
19. Schmidt M, Themann A, Drexler C, Bayer M, Lanzer G, Menichetti E, Lechner S, Wessin D, Prokoph B, Allain JP, Seifried E, Hourfar MK. Blood donor screening for parvovirus B19 in Germany and Austria. Transfusion 2007 47 : 1775 82.
20. Kleinman SH, Glynn SA, Lee TH, Tobler L, Montalvo L, Todd D, Kiss JE, Shyamala V, Busch MP, National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study (REDS-II). Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay. Transfusion 2007 47 : 1756 64.
21. Kerr JR, Curran MD, Moore JE, Coyle PV, Ferguson WP. Persistent parvovirus B19 infection. Lancet 1995 345 : 1118.
22. Cassinotti P, Siegl G. Quantitative evidence for persistence of human parvovirus B19 DNA in an immunocompetent individual. Eur J Clin Microbiol Infect Dis 2000 19 : 886 95.
23. Lefrère JJ, Servant-Delmas A, Candotti D, Mariotti M, Thomas I, Brossard Y, Lefrère F, Girot R, Allain JP, Laperche S. Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood 2005 106 : 2890 5.
24. Matsukura H, Shibata S, Tani Y, Shibata H, Furuta RA. Persistent infection by human parvovirus B19 in qualified blood donors. Transfusion 2008 48 : 1036 7.
25. Blood Products Advisory Committee. Human parvovirus B19 NAT testing for whole blood and source plasma [Internet]. Rockville (MD) : U.S. Food and Drug Administration 2002. p. 299 440 cited 17 Jan 2010]. Available from: http://www.fda.gov/ohrms/dockets/ac/02/transcripts/3913t1.pdf
26. Zanella A, Rossi F, Cesana C, Foresti A, Nador F, Binda AS, Lunghi G, Cappellini MD, Furione M, Sirchia G. Transfusion-transmitted human parvovirus B19 infection in a thalassemic patient. Transfusion 1995 35 : 769 72.
27. Yoto Y, Kudoh T, Haseyama K, Suzuki N, Oda T, Katoh T, Takahashi T, Sekiguchi S, Chiba S. Incidence of human parvovirus B19 DNA detection in blood donors. Br J Haematol 1995 91 : 1017 8.
28. Cohen BJ, Beard S, Knowles WA, Ellis JS, Joske D, Goldman JM, Hewitt P, Ward KN. Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion. Transfusion 1997 37 : 947 52.
29. Shade RO, Blundell MC, Cotmore SF, Tattersall P, Astell CR. Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. J Virol 1986 58 : 921 36.
30. Saldanha J, Lelie N, Yu MW, Heath A, B19 Collaborative Study Group. Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniques. Vox Sang 2002 82 : 24 31.
31. Ferguson M, Walker D, Cohen B. Report of a collaborative study to establish the international standard for parvovirus B19 serum IgG. Biologicals 1997 25 : 283 8.
32. Dorsch S, Kaufmann B, Schaible U, Prohaska E, Wolf H, Modrow S. The VP1-unique region of parvovirus B19: amino acid variability and antigenic stability. J Gen Virol 2001 82 : 191 9.
33. Parsyan A, Addo-Yobo E, Owusu-Ofori S, Akpene H, Sarkodie F, Allain JP. Effects of transfusion on human erythrovirus B19-susceptible or -infected pediatric recipients in a genotype 3-endemic area. Transfusion 2006 46 : 1593 600.
34. Plentz A, Hahn J, Knöll A, Holler E, Jilg W, Modrow S. Exposure of hematologic patients to parvovirus B19 as a contaminant of blood cell preparations and blood products. Transfusion 2005 45 : 1811 5.
35. Kleinman SH, Glynn SA, Lee TH, Tobler LH, Schlumpf KS, Todd DS, Qiao H, Yu MW, Busch MP, for the NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II). A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood 2009 114 : 3677 83.
36. Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM, Pattison JR, Tyrrell DA. Experimental parvoviral infection in humans. J Infect Dis 1985 152 : 257 65.
37. Servant A, Laperche S, Lallemand F, Marinho V, De Saint Maur G, Meritet JF, Garbarg-Chenon A. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002 76 : 9124 34.
38. Blümel J, Eis-Hübinger AM, Stühler A, Bönsch C, Gessner M, Löwer J. Characterization of parvovirus B19 genotype 2 in KU812Ep6 cells. J Virol 2005 79 : 14197 206.
39. Schneider B, Becker M, Brackmann HH, Eis-Hübinger AM. Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2. Thromb Haemost 2004 92 : 838 45.
40. Baylis S. Standardization of nucleic acid amplification technique (NAT)-based assays for different genotypes of parvovirus B19: a meeting summary. Vox Sang 2008 94 : 74 80.
41. Candotti D, Etiz N, Parsyan A, Allain JP. Identification and characterization of persistent human erythrovirus infection in blood donor samples. J Virol 2004 78 : 12169 78.
42. Baylis SA, Shah N, Minor PD. Evaluation of different assays for the detection of parvovirus B19 DNA in human plasma. J Virol Methods 2004 121 : 7 16.
43. Rinckel LA, Buno RB, Gierman TM, Lee DC. Discovery and analysis of a novel parvovirus B19 genotype 3 isolate in the United States. Transfusion 2009 49 : 1488 92.
44. Ekman A, Hokynar K, Kakkola L, Kantola K, Hedman L, Bondén H, Gessner M, Aberham C, Norja P, Miettinen S, Hedman K, Söderlund-Venermo M. Biological and immunological relations among human parvovirus B19 genotypes 1-3. J Virol 2007 81 : 6927 35.
45. Doyle S, Corcoran A. The immune response to parvovirus B19 exposure in previously seronegative and seropositive individuals. J Inf Dis 2006 194 : 154 8.
46. U.S. Food and Drug Administration. Nucleic acid testing (NAT) to reduce the possible risk of parvovirus B19 transmission by plasma-derived products. Rockville (MD) : FDA Center for Biologics Evaluation and Research 2008. FDA draft guidance for industry.
47. Human anti-D immunoglobulin. Strasbourg, France : European Directorate for the Quality of Medicines & HealthCare 2008. Ph Eur monograph 0557.
48. Human anti-D immunoglobulin for intravenous administration. Strasbourg, France : European Directorate for the Quality of Medicines & HealthCare 2008. Ph Eur monograph 1527.
49. Human plasma (pooled and treated for virus inactivation). Strasbourg, France : European Directorate for the Quality of Medicines & HealthCare 2009. Ph Eur monograph 1646.
50. OMCL Guideline for validation of nucleic acid amplification techniques (NAT) for quantitation of B19 virus DNA in plasma pools. Strasbourg, France : European Directorate for the Quality of Medicines & HealthCare 2007. Official Control Authority Batch Release (OCABR) of Biological Substances guideline PA/PH/OMCL (07) 47, DEF.
51. Schmidt M, Mayr-Wohlfart U, Hourfar MK, Schrezenmeier H, Sireis W, Seifried E. Infectivity of B19 positive blood products. Vox Sang 2009 96 Suppl 1 : 54.